IMPORTANT: NEUPRO is for use on the skin only.
Neupro is a transdermal system that provides continuous delivery of rotigotine, a non-ergoline dopamine agonist, for 24 hours following application to intact skin.
Parkinson's Disease (PD)
Neupro (Rotigotine Transdermal System) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
The effectiveness of Neupro was demonstrated in randomized, controlled trials in patients with early-stage Parkinson's disease who were not receiving concomitant levodopa therapy as well as in patients with advanced-stage Parkinson's disease on concomitant levodopa.
Restless Legs Syndrome (RLS)
Neupro (Rotigotine Transdermal System) is indicated for the treatment of moderate-to-severe primary restless legs syndrome.
Published Studies Related to Neupro (Rotigotine)
Transdermal rotigotine in advanced Parkinson's disease: a randomized,
double-blind, placebo-controlled trial. 
Rotigotine, a non-ergot dopamine receptor agonist, offers potential for
continuous dopaminergic stimulation that could avoid the fluctuations observed
with traditional treatments. We conducted a randomized, double-blind,
placebo-controlled trial in Japanese patients with advanced Parkinson's disease
(PD) to investigate the efficacy and safety of rotigotine.
Rotigotine vs ropinirole in advanced stage Parkinson's disease: a double-blind
(PD) patients on concomitant levodopa therapy... CONCLUSIONS: Rotigotine was well tolerated at doses up to 16 mg/24 h and showed
Efficacy and safety of rotigotine in Japanese patients with restless legs
syndrome: a phase 3, multicenter, randomized, placebo-controlled, double-blind,
parallel-group study. 
(RLS)... CONCLUSIONS: Our results showed that rotigotine was effective without major
Drug safety evaluation of rotigotine. 
INTRODUCTION: Rotigotine, a non-ergolinic dopamine-receptor agonist, is currently
approved as monotherapy in early idiopathic Parkinson's disease (IPD), in
moderate to severe idiopathic restless legs syndrome (RLS) and as adjunct therapy
to levodopa in advanced IPD... In addition,
transdermal delivery is associated with local skin reactions, which are usually
mild but may lead to a treatment discontinuation in a minority of patients.
Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind,
placebo-controlled trial in the United States. 
This randomized, double-blinded, placebo-controlled trial (NCT00135993) assessed
efficacy and safety of the dopamine agonist rotigotine in the treatment of
idiopathic restless legs syndrome (RLS) over a 6-month maintenance period. A
total of 505 eligible participants with moderate to severe RLS (IRLS sum score
>or= 15) were randomly assigned to five groups to receive either placebo or
rotigotine (0.5, 1, 2, or 3 mg/24 hr) delivered by once-daily transdermal patch
Clinical Trials Related to Neupro (Rotigotine)
Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro� Requiring Caregiver Support [Completed]
Study to Evaluate the Pharmacokinetics, Safety, Tolerability of Repeated Dose Transdermal Rotigotine in Japanese and Caucasian Subjects [Completed]
Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects [Completed]
Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body [Completed]
The major aim of this study is to investigate and compare the drug amount delivered to the
body after sequential application of two Rotigotine patches of two different formulations
Study in Healthy Volunteers to Prove That Two Rotigotine Patches From Different Manufacturing Sites Deliver Equivalent Drug Amount to the Body [Completed]
Reports of Suspected Neupro (Rotigotine) Side Effects
Drug Ineffective (12),
Parkinson's Disease (12),
Atrial Fibrillation (7),
Fall (6), more >>
Page last updated: 2015-08-10